IMPORTANCE Accumulation of the protein tau is a defining characteristic of several neurodegenerative diseases. Thorough assessment of transgenic (Tg) mouse lines that replicate this process is critical for establishing the models used for testing anti-tau therapeutics in vivo.
T au is a soluble protein that stabilizes microtubules in neurons. 1, 2 In a group of neurodegenerative diseases termed tauopathies, hyperphosphorylated tau accumulates most notably into neurofibrillary tangles (NFTs) in Alzheimer disease (AD). 3 Tauopathies are characterized by progressive dementia, 4 likely resulting from self-propagating misfolded tau (ie, tau prions). 5, 6 After the identification of tau as the main constituent of NFTs in patients with AD, 3, [7] [8] [9] molecular cloning studies 10, 11 found that the tau gene is alternatively spliced into 6 isoforms, giving rise to 0, 1, or 2 N-terminal insertions and 3 or 4 repeats in the repeat domain (RD). The first transgenic (Tg) mouse models expressed 2N4R tau, 12-14 while subsequent models expressed others [15] [16] [17] )
. While most patients with tauopathy do not have mutations, the inclusion of mutations, such as P301S, increases the rate of protein misfolding, accelerating disease progression in a mouse model.
To develop therapeutics for patients with tauopathy, Tg mouse models have been characterized based on the animal's ability to recapitulate several features of neurodegeneration, including tau neuropathology, onset of neurological signs, cognitive and motor deficits, and accumulation of tau prions in the brain (reviewed by van Swieten and Spillantini, 20 by Frank et al, 21 and by Dujardin et al 22 ) . While the currently available models have proven critical for elucidating the molecular pathways underlying disease progression in tauopathies, the lack of comprehensive studies establishing welldefined and reproducible measures of disease progression has hampered the successful discovery of anti-tau therapeutics. The studies reported herein sought to define consistent measures of disease in a Tg mouse model that could be implemented by drug discovery programs for in vivo compound evaluation. PS19 mice are an often-used model expressing 1N4R tau with the P301S mutation, with tau neuropathology developing by 6 months. 23 However, in our analysis, tau accumulation in almost 8-month-old mice was too inconsistent to provide a meaningful measure of disease. We also found that disease onset in the animals ranged from age 3 to 15 months. Furthermore, despite evidence suggesting that tau prion formation is uniform in PS19 mice, 24, 25 we measured 3-fold more tau prions in some animals compared with others tested at the same age. Given the erratic data collected from PS19 mice, we moved to testing the homozygous Tg(MAPT*P301S +/+ ) mouse model, which expresses 0N4R tau with the P301S mutation. 26 Onset of neurological signs was reported to occur in animals aged 5 to 6 months, suggesting that disease onset in these mice is more synchronized. This is in agreement with our finding herein that only 1.9% (3 of 159) of mice lived beyond 8 months. Moreover, using our group's cell-based assay to measure tau prions, 27 we found that the tau prion content was consistent in young animals, and formation of proteinase K (PK)-resistant tau prions was distinguishable from control animals by 5 weeks. As expected from the reported development of thioflavin S-positive aggregates in Tg(MAPT*P301S +/+ ) mice aged 5 to 6 months, 26 we measured robust tau pathology in 6-monthold mice, but observed a lack of immunostaining in animals aged 4.5 months and younger. Our results establish a consistent baseline across 3 measures of disease in Tg(MAPT*P301S +/+ ) mice, including neuropathology, disease onset, and tau prion formation. In contrast, we found disease progression in the PS19 mice to be so variable that approximately 900% more animals would be required to adequately power an efficacy study than Tg(MAPT*P301S +/+ ) mice. Moreover, by using a cell-based assay to quantify tau prion formation in the mice, we identified an early end point for efficacy studies that directly measures biologically active tau.
Methods

Study Design
In this time course study, cohorts of Tg and control mice were euthanized at defined intervals. Collected brains were bisected sagittally. One half was frozen and used to measure the tau prion content, while the other half was fixed for immunostaining with anti-tau antibodies. All animals were maintained at the Hunters Point Animal Facility at the University of California, San Francisco, and all experiments were performed at the Mission Bay Campus of the University of California, San Francisco. Study animals were PS19, homozygous and hemizygous Tg(MAPT*P301S), and B6/J mice. The study dates were August 9, 2010, to October 3, 2016 . Animals were maintained in a facility accredited by the Association for Assessment and Accreditation of Laboratory Animal Care in accord with the Guide for the Care and Use of Laboratory Animals.
28 All procedures were approved by the Tau prions were measured using a cell-based assay. Neuropathology was measured by determining the percentage area
Key Points
Question What is a reproducible baseline measure of disease progression in a tauopathy animal model that we can use to determine compound efficacy in drug discovery programs? Findings A total of 1035 mice were used in this time course study. In 1 line of transgenic mice, tau prions were reproducibly detected by age 5 weeks, while extensive variability in another mouse line renders the model unusable for efficacy studies.
Meaning Future studies assessing the ability of small molecules or other therapeutic strategies to slow or halt neurodegeneration should directly measure the ability of the compound to halt tau prion formation in an animal model that exhibits consistent disease kinetics.
positive for immunostaining in defined brain regions. A separate cohort of mice was aged until each mouse developed neurological signs as determined by trained animal technicians to assess mortality.
Tau Prion Assay
A 10% brain homogenate was prepared using frozen halfbrains from B6/J and Tg(MAPT*P301S) mice in calcium and magnesium-free 1 × Dulbecco phosphate-buffered saline (DPBS) (Thermo Fisher). Protein aggregates were precipitated using sodium phosphotungstic acid (Sigma), as described previously. 30, 31 Protein pellets were diluted 1:4 in 1 × DPBS and tested in the cell aggregation assay. Culture and assay conditions for human embryonic kidney (HEK293) cells expressing Tau(4RD*LM)-YFP (1) 32 were previously described, where LM indicates the 2 familial mutations P301L and V337M and YFP indicates yellow fluorescent protein. 27 After 4 days' incubation, 384-well plates were imaged using the IN Cell Analyzer 6000 (GE Healthcare Life Sciences). 4′,6-Diamidino-2-phenylindole and fluorescein isothiocyanate images were collected from 4 regions in each well, which were analyzed using the IN Cell Developer software. Each sample was tested independently 3 times. Additional eMaterials and eMethods are available in the eAppendix in the Supplement. The significance level in the study was set at 2-sided P < .05 for statistical analyses performed with a t test.
Results
A total of 1035 mice were used in this time course study. These included PS19 mice (51.2% [126 of 246] 
Variability of Tauopathy Progression in PS19 Mice
Two-month-old PS19 mice 23 were inoculated intracranially with 30 μL of either 1 × DPBS or 1% control brain homogenate diluted in 5% bovine serum albumin. The mice were collected at age 31 weeks, and the formalin-fixed brains were assessed for tau neuropathology using the antibody AT8 (phosphorylated tau at Ser202/Thr205) (eFigure 1A in the Supplement). Studies of central nervous system disease proved infeasible due to random variations in tau neuropathology. In a separate group of mice used to assess disease onset, shown in a Kaplan-Meier plot (red line in eFigure 1B in the Supplement), neurological signs required 3 to 15 months to develop. When we performed our initial PS19 mouse survival studies, we were unaware of the variation in the published mortality data (black line in eFigure 1B in the Supplement).
23
To determine the tau prion content of the brains from PS19 mice, we collected frozen half-brains from mice aged 20 to 38 weeks and measured the tau prion levels using a cell-based assay.
31 Clarified brain homogenate was incubated with HEK293T Figure 1A and eFigure3BintheSupplement). To determine the age at which Tg(MAPT*P301S +/+ ) mice became distinguishable from B6/J mice, nonparametric curves were fit to the data, and the 95% CI was calculated. Significant separation between the 2 lines was defined as the age at which the 95% CIs no longer overlapped. Tg(MAPT*P301S +/+ ) mice were significantly different from B6/J mice at age 4.4 weeks using D × A per cell (Figure 1B and C) Figure 2A) . Through 12 weeks, both male and female mice showed a linear increase in tau prion formation ( Figure 2B ), suggesting that assays measuring the reduction in tau prion propagation in young Tg(MAPT*P301S +/+ ) mice might facilitate anti-tau drug discovery. The tau prion content in older animals was more variable than in younger mice.
Neurological Dysfunction in Tg(MAPT*P301S
Onset of neurological signs was observed in a separate group of Tg(MAPT*P301S +/+ )m i c ea ta p p r o x i m a t e l ya g e2 4w e e k s ( Figure 2C ). Females developed degenerative signs before males. The high variability in tau prions measured in the cell assay at the 20-week time point coincides with onset of neurological signs. ) and B6/J mice aged 6, 12, 18, and 24 weeks, by immunostaining with AT8, MC1 (misfolded tau), HT7 (human tau), and glial fibrillary acidic protein (GFAP) antibodies. The sensorimotor cortex, striatum, piriform cortex and amygdala, hippocampus, thalamus, hypothalamus, midbrain, and pons were evaluated in all animals.
No AT8 neuropathology was found in B6/J mice ( Figure 3 and eFigure 4 in the Supplement). Comparing AT8 deposition between 6-week-old B6/J and Tg(MAPT*P301S +/+ ) mice, a small but significant increase in the midbrain and pons was found. A much larger increase in AT8 staining was observed in the brains of Tg(MAPT*P301S +/+ ) mice at age 24 weeks compared with 6-week-old animals as well as compared with 24-week-old B6/J mice. The MC1 and HT7 immunostaining yielded similar results, with significant detection of tau aggregates in 24-week-old Tg(MAPT*P301S +/+ ) mice but minimal immunostaining in younger animals (eFigure 4 and eFigure 5 in the Supplement).
In parallel, measuring astrogliosis with the GFAP antibody (eFigure 6 in the Supplement) showed that reactive astrocytes were significantly increased in the thalamus, midbrain, and pons of 24-week-old Tg(MAPT*P301S +/+ ) mice compared with 6-week-old Tg(MAPT*P301S +/+ ) animals. As expected, GFAP immunostaining was unchanged through age 24 weeks in the B6/J mice.
Stability of Tau Prions From Tg(MAPT*P301S +/+ ) Mice
Given the neuropathological differences between 6-weekold and 24-week-old Tg(MAPT*P301S +/+ ) mice, we examined tau prion stability from animals aged 6 weeks and 24 weeks under denaturing conditions ( Figure 4 ). Tau prions from aged Tg(MAPT*P301S +/+ ) mice were previously found to be resistant to 1 μg/mL of PK. 33 Testing tau prions from two 6-weekold and 24-week-old Tg(MAPT*P301S +/+ ) mice, 1 mg of detergent-insoluble protein was digested in 0, 0.5, 1, 2.5, or 5 μg of PK for 30 minutes ( Figure 4A and B). The remaining protein was analyzed by immunoblot using the human tau antibody Tau12. Tau prions from both the 6-week-old and 24-week-old mice were resistant to 1 μg of PK, were partially digested by 2.5 μg of PK, and were completely digested by 5 μg of PK. We also tested stability by sequential extraction in detergents with an increasing propensity to solubilize aggregated protein ( Figure 4C ). This method identified differences in ) mouse (solid dark blue line). The 95% CI was calculated for both mouse lines (dotted lines), and the age at which the 2 95% CIs no longer overlapped (age 4.4 weeks) was determined (light blue line). C, The inset (blue box) in B is enlarged in C.
Kinetics of Human Mutant Tau Prion Formation in the Brains of 2 Transgenic Mouse Lines
Original protein solubility in several Tg mouse models. 23, [34] [35] [36] Brain homogenates were digested in high salt, high salt plus Triton X-100, radioimmunoprecipitation buffer, 2% sodium dodecylsulfate, and 66% formic acid; the supernatant from each extraction was collected for immunoblot analysis, while the protein pellet was digested in the subsequent buffer. Tau prions ) mice at age 24 weeks compared with mice at age 6 weeks (P = .02 for SMCx, P = .004 for Str, P < .001 for Pir, P < .001 for HC, P < .001 for Thal, P < .001 for HTH, P < .001 for Mid, and P < .001 for pons). Data are given as the means. B and C, Comparing AT8 neuropathology by brain region in B6/J and Tg(MAPT*P301S +/+ ) mice. AT8 pathology was increased in the Mid (P = .02) and pons (P < .001) of 6-week-old Tg(MAPT*P301S +/+ ) mice (B) compared with B6/J mice (C) and was increased in all brain regions in 24-week-old animals (P = .01 for SMCx, P = .003 for Str, P < .001 for Pir, P < .001 for HC, P < .001 for Thal, P < .001 for HTH, P < .001 for Mid, and P < .001 for pons). Data are shown as the mean (SD). a P < .05. from 6-week-old and 24-week-old mice demonstrated similar resistance in all 5 detergents. Together, these stability data argue that tau prions in 6-week-old and 24-week-old Tg(MAPT*P301S +/+ ) mice are similar.
Tau Prion Formation Kinetics Modified by Transgene Dose
To determine the influence of transgene dose on tau prion formation, we collected frozen half-brains from 6-week-old to 24-week-old hemizygous Tg(MAPT*P301S +/− ) mice ( Figure 5A and B and eFigure 7A in the Supplement). Incubating tau prions isolated from Tg(MAPT*P301S +/− ) mice with Tau(4RD*LM)-YFP(1) cells showed an increase in tau prion formation with age. After calculating the 95% CI for these data, we determined that Tg(MAPT*P301S +/− ) mice can be distinguished from B6/J mice at age 7.9 weeks using D × A per cell (black line in Figure 5B and eFigure 7B in the Supplement) and at age 7.3 weeks using percentage cells with aggregates (blue line in eFigure 8B and C in the Supplement). Homozygous Tg(MAPT*P301S +/+ ) mice were significantly different from hemizygous animals before age 6 weeks (gray line in Figure 5B and green line in eFigure 8 in the Supplement). The concentration of tau prions in aged Tg(MAPT*P301S +/− ) mouse brains remained below the concentration in 12-week-old homozygous mice.
We also examined tau and GFAP neuropathology in Tg(MAPT*P301S +/− ) mice aged 6, 12, 18, and 24 weeks. AT8
neuropathology was similar in 6-week-old B6/J and Tg(MAPT*P301S +/− ) mice (eFigure 9 in the Supplement) and in 6-week-old and 24-week-old Tg(MAPT*P301S +/− ) mice (eFigure 10A and B in the Supplement). Significant, although minute, increases in AT8 immunostaining were quantified in the midbrain and pons of 24-week-old Tg(MAPT*P301S +/− ) mice relative to B6/J mice (eFigure 9 in the Supplement).
In comparison, tau neuropathology in 24-week-old Tg(MAPT*P301S +/− ) mice was significantly reduced compared with 24-week-old homozygous mice ( Figure 5C ). Tau immunostaining using the MC1 and HT7 antibodies showed similar results as obtained with the AT8 antibody (eFigure 10C-F in the Supplement). In addition, no differences in astrogliosis were observed between 6-week-old and 24-week-old Tg(MAPT*P301S +/− ) mice with the exception of a small decrease in the midbrain (eFigure 11 in the Supplement). Consistent with the tau prion quantification assay, we observed remarkably less neuropathology in 24-week-old hemizygous mice compared with homozygous mice. Finally, we compared the spontaneous onset of neurological signs in a separate cohort of animals (green line in eFigure 1B in the Supplement). While Tg(MAPT*P301S +/− ) mice exhibited a similar rate of disease onset as observed in PS19 mice, approximately 40% fewer animals would be required to adequately power an efficacy study using this line (eTable in the Supplement). However, compared with the homozygous mice, almost 600% more Tg(MAPT*P301S +/− ) animals would be required.
Discussion
Transgenic animal models have contributed greatly to elucidating the molecular mechanisms that feature in neurodegenerative disorders. For tauopathies, mouse models replicating neuropathological lesions seen in human patients have resulted in important discoveries regarding the spreading of misfolded tau throughout the brain. However, to focus efforts on discovering drugs that intervene with tau prion replication, ) mice at age 6 weeks and 24 weeks (n = 2) and digested with increasing concentrations of proteinase K (PK) (0-5 μg) at 37°C for 30 minutes (while shaking). Protein remaining after partial digestion was pelleted by ultracentrifugation and analyzed by Western blot with the Tau12 antibody. B, Quantification of immunoblots shown in A were normalized to 0 μg of PK. Data are shown as the mean (SD) for the 2 mice at each time point. C, Aggregated protein was isolated from 6-week-old and 24-week-old male Tg(MAPT*P301S +/+ ) mice (n = 2) using a series of increasingly stringent buffers, including high salt (HS), high salt plus Triton X-100 (HST), radioimmunoprecipitation buffer (RIPA), 2% sodium dodecylsulfate (SDS), and 66% formic acid (FA). Soluble fractions were collected after digestion in each buffer and were analyzed by Western blot with the Tau12 antibody.
Kinetics of Human Mutant Tau Prion Formation in the Brains of 2 Transgenic Mouse Lines
Original In contrast with the PS19 mice, tau prions were quantifiable in 5-week-old Tg(MAPT*P301S +/+ ) mice, and the rate of tau prion formation in young Tg(MAPT*P301S +/+ ) mice consistently increased regardless of sex. While neuropathological changes were reproducible in Tg(MAPT*P301S +/+ ) mice, significant lesions were only found in the 24-week-old mice. Given this stark difference between the neuropathological changes in 6-week-old and 24-week-old Tg(MAPT*P301S +/+ ) mice, the biochemical properties of tau prions isolated from Tg(MAPT*P301S +/+ ) mice at both ages were compared, and similar resistance to several protein-denaturing conditions was observed, irrespective of animal age. These similar properties suggest that in vivo assays measuring the influence of drug candidates on the tau prion content in young mice are feasible. Using young Tg(MAPT*P301S +/+ ) mice instead of older animals (or PS19 mice) should permit a more rapid measurement of tau prions in the brains of treated animals.
There are 3 likely sources contributing to the identified differences between these 2 models. First, the Tg(MAPT*P301S +/+ ) mice are on a congenic B6/J background, but the PS19 mice are on a hybrid B6C3 background. The PS19 mice are available on a congenic B6/J background from The Jackson Laboratory, but the line is not actively bred. More important, because the PS19 mice are most commonly used on the B6C3 background, we chose to perform our studies using that version of the model. The variability of disease onset conferred by a mixed-strain background has been well documented in scrapie transmission studies, [53] [54] [55] [56] [57] suggesting that it may have a role in tauopathy progression as well. Second, the promoter used to drive . Tau prions were quantified from each animal by averaging 3 independent preparations. B, A nonparametric curve was fit to the data in A (solid light blue line). The 95% CI was calculated (dotted lines) and compared with curves generated from the B6/J (orange line) and Tg(MAPT*P301S +/+ ) (dark blue lines) data. The age at which the 95% CIs for the Tg(MAPT*P301S +/− ) and Tg(MAPT*P301S +/+ ) mice no longer overlapped occurred before 6 weeks (gray line). The separation in 95% CIs with the B6/J mice occurred at 7.9 weeks (black line). C, AT8 neuropathology measured in the sensorimotor cortex (SMCx), striatum (Str) , piriform cortex and amygdala (Pir), hippocampus (HC), thalamus (Thal) , hypothalamus (HTH), midbrain (Mid), and pons of 24-week-old Tg(MAPT*P301S +/− ) mice was reduced in all brain regions compared with Tg(MAPT*P301S +/+ ) mice (P = .008 for SMCx, P = .008 for Str, P < .001 for Pir, P <.001 for HC, P < .001 for Thal, P < .001 for HTH, P < .001 for Mid, and P < .001 for pons). Data are given as the mean (SD). a P <.05. 
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Limitations
As Tg models of neurodegeneration that develop spontaneous tau prions, it is unclear if the PS19 and Tg(MAPT*P301S) mouse models develop tau prion strains that are consistent with the tau prion strains present in humans with tauopathy. Moreover, the lack of therapeutics with demonstrated success in clinical trials limits our ability to evaluate the sensitivity of this efficacy model against control compounds.
Conclusions
The results reported herein have important implications for the ongoing efforts to discover anti-tau therapeutics and illustrate the need for uniform disease progression in efficacy models. In establishing the kinetics of tau prion replication in Tg(MAPT*P301S 
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SUPPLEMENTARY MATERIALS AND METHODS
Mouse samples
Wild-type C57BL/6J, or B6/J, mice and PS19 mice 1 (sometimes referred to as P301S mice) were purchased from the Jackson Laboratory. B6-Tg(Thy1-MAPT*P301S)2541 2 mice (sometimes referred to as the hTau.P301S model) were originally generated on a C57BL/6JxCBA/ca background and were subsequently backcrossed for eight generations with marker-assisted backcrossing to confirm the genetic background of the mice was close to 100% C57BL/6J. The mice were then intercrossed to generate homozygous animals. Homozygous B6-Tg(Thy1-MAPT*P301S), or Tg(MAPT*P301S +/+ ), mice were maintained by intercrossing while the hemizygous P301S +/-mice were generated by backcrossing homozygous animals with wild-type B6 mice. All animals were assessed for routine health daily and received two tests for neurological illness each week. Mice were euthanized using CO 2 followed by cervical dislocation. The brain from each mouse was then removed and bisected at the midline, with the left hemisphere snap-frozen for biochemical analysis and the right hemisphere fixed in 10% buffered formalin for neuropathology. Experiments were performed with approximately half males and half females, unless noted otherwise.
Inoculations
Two-month-old PS19 mice were anesthetized with isoflurane and inoculated with 30 L 1× DPBS or 1% control brain homogenate diluted in 5% bovine serum albumin into the right parietal lobe. All animals were then assessed twice a week and were euthanized, as described above, 160 days post inoculation (31 weeks of age).
Tau prion assay of PS19 mouse brains
A 10% brain homogenate was prepared using frozen brains from PS19 mice in calcium-and magnesium-free 1× DPBS. Brain homogenates were clarified at 1,000 × g, and protein concentration was quantified using the bicinchoninic acid protein assay (BCA; Pierce). Concentrations were adjusted to 2 mg/mL and diluted 1:40 in 1× DPBS. Samples were incubated in 1.25% Lipofectamine 2000 (Thermo Fisher) for 1.5 h, and a final concentration of 78.75% OptiMEM (Thermo Fisher) was added. Samples were then incubated with Tau(4RD*LM)-YFP(2) cells 3 for 3 d prior to imaging. Each sample was tested independently twice.
Immunohistochemistry
The formalin-fixed full brains from 31-week-old PS19 mice and half brains from 6-, 12-, 18-, and 24-week-old mice were cut coronally into four pieces, processed through graded alcohols, cleared with xylene, infiltrated with paraffin, and embedded. Once embedded, the tissue was cut into 8 m slices, collected on slides, deparaffinized, and used for immunohistochemistry. Primary antibody incubation was performed overnight at room temperature with AT8 (1:250 after autoclaving for 10 min; Thermo Fisher), MC1 (1:400 after autoclaving for 10 min; kindly provided by Peter Davies, Albert Einstein College of Medicine, Bronx, NY), HT7 (1:2,000 after steaming for 20 min; Thermo Fisher) or glial fibrillary acidic protein (GFAP; 1:500; Dako). Mouse on Mouse Blocking Reagent (Vector Laboratories) was used to block slides stained with mouse antibodies (AT8, MC1, and HT7). The Vectastain ABC peroxidase kit (Vector Laboratories) was used to detect bound antibody and was visualized using 3-3 -diaminobenzidine. The slides were counterstained using hematoxylin. Slides containing PS19 mouse brains were imaged on a Zeiss Axio Imager.A1. The B6/J and Tg(MAPT*P301S) slides were imaged using the Zeiss AxioScan.Z1.
Digital images of each slide were then analyzed using Zen Analysis software (Zeiss). For each antibody, a pixel intensity threshold was determined, and the same threshold was applied to all slides stained with that antibody. Regions of interest were drawn around the sensorimotor cortex, striatum, piriform cortex and amygdala, hippocampus, thalamus, hypothalamus, midbrain, and pons, and the percentage of positive pixels was determined in each region.
Proteinase K digestion
Brain homogenate from two 6-week-old and two 24-week-old male Tg(MAPT*P301S +/+ ) mice were tested for tau resistance to proteinase K (PK) (Thermo Fisher). Nine volumes of the 10% brain homogenates were added to one volume of 10× detergent extraction buffer [5% (vol/vol) Nonidet P-40 (NP-40), 5% (wt/vol) sodium deoxycholate (DOC) in PBS], vortexed, and incubated on ice for 15 min. After samples were centrifuged at 1,000 × g for 5 min, the supernatant was collected and the protein was quantified by BCA. Samples were diluted to 1 mg of protein in a final volume of 400 L 1× detergent buffer. PK was added to each sample for final concentrations of 0, 0.5, 1, 2.5, and 5 g, and samples were digested at 37 °C for 30 min while shaking at 550 rpm in an Eppendorf ThermoMixer. PK digestion was terminated by adding phenylmethylsulfonyl fluoride (PMSF; Sigma) to a final concentration of 5 mM. Sarkosyl was added to each sample for a final concentration of 2%, and the samples were centrifuged at 100,000 × g for 1 h at 4 °C. The supernatants were removed from PK-digested samples by aspiration, and the pellets were resuspended in 1× NuPAGE lithium dodecyl sulfate (LDS) sample buffer with 2.5% (vol/vol) -mercaptoethanol (BME; Sigma) and 1× NuPAGE Reducing Agent. For non-PK-digested samples, supernatant was diluted in an equal volume of 2× NuPAGE LDS sample buffer with 1× reducing agent. All samples were boiled for 10 min and analyzed by immunoblotting.
Sequential detergent extraction
Aggregated tau was isolated from two 6-week-old and two 24-week-old Tg(MAPT*P301S +/+ ) mice using the multidetergent extraction method described in detail in Watts et al. 4 Briefly, 10% brain homogenate was exposed to increasingly stringent buffers to isolate aggregated tau prions. After the addition of each buffer, samples were sonicated in a water-bath sonicator for 5 min and centrifuged at 100,000 × g for 30 min at 4 °C. The supernatant was removed following each spin, and the resulting pellet was resuspended in the next buffer. For each step, 100 L buffer was used. The buffers used, in order, were high salt [(HS); 750 mM NaCl and 5 mM EDTA (Thermo Fisher)]; high salt + Triton X-100 [(HST); 50 mM TrisHCl, pH 7.5 (Thermo Fisher); 750 mM NaCl; 5 mM EDTA; and 1% (vol/vol) Triton X-100 (Sigma)]; radioimmunoprecipitation buffer [(RIPA); 50 mM TrisHCl, pH 7.5; 150 mM NaCl; 5 mM EDTA; 1% (vol/vol) NP-40; 0.5% (wt/vol) DOC; and 0.1% (wt/vol) sodium dodecyl sulfate (SDS; Thermo Fisher)]; SDS [50 mM TrisHCl, pH 7.5; 2% (wt/vol) SDS], and formic acid [(FA); 66% FA in ddH 2 O] . Following FA, 80 L of the supernatant was removed and placed in an Eppendorf tube where the acid was evaporated using a speed-vacuum centrifuge.
After HS, HST, RIPA, and SDS extractions, 60 L of supernatant was added to 40 L 4× NuPAGE LDS sample buffer while the FA pellet was resuspended in 40 L 1× NuPAGE LDS sample buffer. Samples were diluted in 1× Dulbecco's phosphate-buffered saline (DPBS) (HS-1:30; HST-1:10; RIPA-1:2; SDS-1:2; FA-none) with 1× NuPAGE Reducing Agent and boiled for 10 min prior to immunoblotting.
Immunoblotting
All samples prepared for immunoblotting were loaded onto an 8% Bolt Bis-Tris gel (Thermo Fisher). SDS-PAGE was performed using the MES buffer system, and protein was transferred to polyvinylidene fluoride (PVDF) membranes using a semi-dry transfer. Membranes were blocked using blocking buffer [5% (wt/vol) nonfat milk in 1× Tris-buffered saline containing 0.05% (vol/vol) Tween 20 (TBST)] for 30 min at room temperature and then incubated in Tau12 primary antibody (1:10,000) overnight at 4 °C. Tau12 was isolated as described 5 . Membranes were washed three times with 1× TBST before incubating in horseradish peroxidase-conjugated secondary antibody (Bio-Rad) diluted in blocking buffer for 1 h at room temperature. Blots were again washed three times in 1× TBST and developed using the enhanced chemiluminescent detection system (GE Healthcare) for exposure to X-ray film.
Statistical analysis
Data are presented as mean ± standard deviation. Data from the cell aggregation assay were analyzed by fitting nonparametric curves to the average data points collected from all mice for the B6/J, Tg(MAPT*P301S +/+ ), and Tg(MAPT*P301S +/-) mouse lines. The 95% confidence interval (CI) was determined, and significant differences between each mouse line were verified as the point at which the CIs no longer overlapped. Onset of neurological symptoms between female and male Tg(MAPT*P301S +/+ ) mice was compared using a log-rank (Mantel-Cox) test. Mean and variance of survival time presented in eFigure 1 was calculated for each mouse line. These parameters were then used to conduct a power analysis for a range of treatment effects with =.05 and a power of 80%. Statistical comparisons of neuropathology scores between B6/J and either Tg(MAPT*P301S +/+ ) or Tg(MAPT*P301S +/-) mice were performed using a two-tailed Student's t test with unequal variance. Significance was determined with a P value <.05. +/-) mice (solid pink line), and the 95% CI was calculated (dotted lines). These data were compared with curves generated from the B6/J (black lines) and Tg(MAPT*P301S +/+ ) (gray lines) mouse data. The age at which the 95% CI for the Tg(MAPT*P301S +/-) mice no longer overlapped with the 95% CI for the Tg(MAPT*P301S +/+ ) mice occurred prior to 6 weeks (green line), and the age at which the Tg(MAPT*P301S +/-) data no longer overlapped with the B6/J data occurred at 7.9 weeks (blue line). Inset (green box) shown in Fig. 5G . +/-) mice (solid pink line), and the 95% CI was calculated (dotted lines). These curves were compared with curves generated from the B6/J (black lines) and Tg(MAPT*P301S +/+ ) (gray lines) mouse data. The age at which the 95% CI for the Tg(MAPT*P301S +/-) mice no longer overlapped with the homozygous mice occurred prior to 6 weeks (green line). The age at which the Tg(MAPT*P301S +/-) and B6/J 95% CIs no longer overlapped occurred at 7.3 weeks (blue line). Inset (green box) (B) shown in (C) . eFigure 10. Tg(MAPT*P301S +/-) mice develop minimal tau neuropathology by 24 weeks of age. AT8, MC1, and HT7 immunostaining was measured in the sensorimotor cortex (SMCx), striatum (Str) ,
